Komboglyze
saxagliptin / metformin hydrochloride
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Komboglyze. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Komboglyze.
For practical information about using Komboglyze, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Komboglyze : EPAR - Summary for the public (PDF/89.04 KB)
First published: 16/12/2011
Last updated: 02/08/2017
EMA/806986/2011 -
-
List item
Komboglyze : EPAR - Risk-management-plan summary (PDF/169.74 KB)
First published: 22/03/2021
Last updated: 22/09/2022
Authorisation details
Product details | |
---|---|
Name |
Komboglyze
|
Agency product number |
EMEA/H/C/002059
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Therapeutic area (MeSH) |
Diabetes Mellitus, Type 2
|
Anatomical therapeutic chemical (ATC) code |
A10BD10
|
Publication details | |
---|---|
Marketing-authorisation holder |
AstraZeneca AB
|
Revision |
20
|
Date of issue of marketing authorisation valid throughout the European Union |
24/11/2011
|
Contact address |
AstraZeneca AB |
Product information
30/05/2023 Komboglyze - EMEA/H/C/002059 - IAIN/0055
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Drugs used in diabetes
-
Combinations of oral blood glucose lowering drugs
Therapeutic indication
Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.
Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.
Assessment history
News
-
19/05/2017
-
14/10/2016
-
26/07/2013
-
26/07/2013
-
26/03/2013
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 201318/01/2013
-
07/11/2012
-
21/09/2012